You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

427 Results
Drug
Other Name(s): Padcev®
Quick Link(s): Drug Monograph, Patient Info Sheet
Aug 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Cetuximab with Irinotecan - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cetuximab,
irinotecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
isatuximab (Unfunded),
bortezomib,
dexamethasone,
lenalidomide (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
High Cost Therapy Funding Program
    Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tebentafusp
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
epcoritamab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
belantamab mafodotin (Compassionate),
bortezomib,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Drug
Other Name(s): Epkinly™
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Aug 2025
Drug
Other Name(s): Kimmtrak®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Aug 2025
Drug
Other Name(s): Caelyx®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Aug 2025
Drug
Other Name(s): Vidaza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Drug
Other Name(s): Keytruda®
Quick Link(s): Drug Monograph, Patient Info Sheet
Updated
Sep 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Sep 2025

Pages